Dr. Stephen Jones discusses TEAM trial findings that suggest exemestane improves breast cancer survival over tamoxifen at 2.75 years of follow-up. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.